Lab
Focal Point, INC.
Focal Point, INC. was paid $212K by Medicaid between Dec 2020 and Jan 2022, across 9 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 40% of everything it billed.
33Billing provider infoFOCAL POINT, INC.
NEWPORT BEACH, CA 92663
NEWPORT BEACH, CA 92663
33aNPI1023606258assigned 01/04/2021
33bProvider typeClinical Medical Laboratory
28Total paid$212K
24GClaims5,869
24DCodes billed9
24AFirst – last monthDec 2020 – Jan 2022
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#283 of 561
Median peer was paid$222K
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 69 | $4K | |
| 2021 | 3,567 | $126K | |
| 2022 | 2,233 | $82K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 40% | 1,527 | 863 | $85K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 38% | 1,260 | 891 | $80K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 10% | 1,193 | 845 | $22K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.7% | 393 | 286 | $8K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.3% | 144 | 92 | $5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 46 | 39 | $4K |
| 86769 | 1.7% | 81 | 55 | $4K | |
| 99072 | 1.4% | 432 | 294 | $3K | |
| 99000 | <1% | 793 | 486 | $2K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGARCIA SUAREZ, PAUL (PRESIDENT)
Parent organizationFOCAL POINT, INC.